Dr. Keirstead was presented with this achievement for his instrumental innovation in biotechnology. As the Chairman of Immunis, Dr. Keirstead oversees the development of an investigational stem cell secretome product (STEM) to serve as an immunomodulator in age-related diseases. Immunis recently began patient enrollment for their FDA-approved Phase 1/2a clinical trial to test the safety and tolerability of STEM in patients with muscle atrophy related to knee osteoarthritis.
“I am honored to be a part of the vibrant business and research ecosystem of Orange County,” said Dr. Keirstead.
The Immunis team is honored that OCBJ has recognized the leadership and innovation of its Chairman and is looking forward to exploring the potential benefits of STEM in humans. Congratulations Dr. Keirstead!
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.